Abdelrazek Mohamed A, Elghwab Ahmed I, Tabll Ashraf A, Elsayed Elsherbiny H, El Behery Mohammed
Department of Research and Development, Biotechnology Research Center, New Damietta 34517, Egypt.
Sherbin Central Hospital, Ministry of Health and Population, Shirbin City 35661, Egypt.
World J Virol. 2025 Jun 25;14(2):106479. doi: 10.5501/wjv.v14.i2.106479.
Treatment response to direct-acting antivirals (DAAs) is a challenging issue and the identification of non-responders patients is very important.
To evaluate the relation between baseline serum levels of hyaluronic acid (HA) and type III procollagen N-peptide (PIIINP) with direct-acting antivirals treatment failure in Egyptian patients with chronic hepatitis C.
Hepatitis C patients (responders and non-responders to sofosbuvir/daclatasvir) were tested for HA and PIIINP using sensitive chemiluminescent immunoassay.
There were distinctly higher PIIINP ( = 0.0003) and HA ( < 0.0001) levels in non-responders than responders patients with a good ability for distinguishing non-responders from patients with sustained virological response (area under the curve = 0.766 for HA and 0.684 for PIIINP). Logistic regression analysis revealed that the HA × PIIINP is the model with the highest predictive ability (area under the curve = 0.809). Diagnostic performances were superior to each marker alone with good sensitivity (74.7%), specificity (74%), positive predictive (68.3%), negative predictive values (79.6%) and accuracy (74.3%). The multiplication of HA × PIIINP is correlated significantly ( < 0.05) with elevated liver enzymes ( = 0.212), decreased albumin ( = -0.26), elevated aspartate aminotransferase-platelet ratio index ( = 0.223) and elevated fibrosis-4 score ( = 0.216) scores.
These findings suggested the remarkable role of fibrogensis markers HA and PIIINP in the prediction of hepatitis C virus DAAs treatment response. Multiplying HA with PIIINP values increase the sensitivity to detect treatment success and thus may aim to improve treatment duration and the disease control.
直接作用抗病毒药物(DAAs)的治疗反应是一个具有挑战性的问题,识别无反应患者非常重要。
评估埃及慢性丙型肝炎患者基线血清透明质酸(HA)和III型前胶原N端肽(PIIINP)水平与直接作用抗病毒药物治疗失败之间的关系。
使用灵敏的化学发光免疫分析法对丙型肝炎患者(索磷布韦/达卡他韦治疗的反应者和无反应者)进行HA和PIIINP检测。
无反应者的PIIINP水平(P = 0.0003)和HA水平(P < 0.0001)明显高于反应者,HA和PIIINP区分无反应者和持续病毒学应答患者的能力良好(HA曲线下面积 = 0.766,PIIINP曲线下面积 = 0.684)。逻辑回归分析显示,HA×PIIINP是预测能力最高的模型(曲线下面积 = 0.809)。其诊断性能优于单独的每个标志物,具有良好的敏感性(74.7%)、特异性(74%)、阳性预测值(68.3%)、阴性预测值(79.6%)和准确性(74.3%)。HA×PIIINP的乘积与肝酶升高(P = 0.212)、白蛋白降低(P = -0.26)、天冬氨酸转氨酶-血小板比值指数升高(P = 0.223)和纤维化-4评分升高(P = 0.216)显著相关(P < 0.05)。
这些发现表明纤维化标志物HA和PIIINP在预测丙型肝炎病毒DAAs治疗反应中具有显著作用。将HA与PIIINP值相乘可提高检测治疗成功的敏感性,从而可能有助于缩短治疗时间和控制疾病。